Chartwell Partners is pleased to have worked with gamma delta T cell therapy company, Adicet Bio, to recruit Julie Maltzman, MD, as Chief Medical Officer. She joins Adicet from IconOVir Bio where she served as Chief Medical Officer leading, designing, and executing on a clinical development program focused on refractory solid tumors. Prior to that,…
Category: BIOPHARMACEUTICALS
Neuroscience biopharmaceutical company, Xenon Pharmaceuticals, has hired Matt Ronsheim, PhD, as its Chief Operating Officer where he will oversee CMC, Program Management and Quality Assurance. We are delighted to have recruited five executives to Xenon as the company continues its evolution towards the commercialization of its first product candidate. Dr. Ronsheim has 25 years of experience…
We are honored to continue our work with Protagonist Therapeutics, recruiting I&I R&D leader, Newman Yeilding, MD, as the Company’s Executive Vice President and Chief Scientific Advisor. Throughout his career, including 17 years with Janssen, Dr. Yeilding has successfully championed multiple novel programs through research, development and commercialization in rheumatology, gastroenterology, dermatology, and pediatrics. Dr….
Chartwell’s Biopharmaceuticals practice worked with clinical stage, precision medicine leader, Frontier Medicines, to recruit Gerardo Ubaghs as Chief Financial Officer. This appointment follows our prior work recruiting Frontier’s Chief Medical Officer, Andrew Krivoshik, MD, PhD, and the Company’s Senior Vice President and Head of Oncology and Inflammatory Disease Research, Lata Jayaraman, PhD. Mr. Ubaghs is…
Chartwell Partners is pleased to have worked with our long-standing client, Akebia Therapeutics, to recruit Mr. Ostrowski as Chief Financial Officer and Chief Business Officer. Mr. Ostrowski is an important addition to Akebia’s leadership team as the Company executes its US launch of Vafeso® for the treatment of anemia due to chronic kidney disease in…
Based in the Bay Area, Attovia Therapeutics is creating a pipeline of biotherapeutics with an initial focus on immune-mediated diseases. The company leverages Attobody™, a novel biologics platform, to generate small format biparatopic binders that offer stronger efficacy and a broader universe of druggable epitopes compared to traditional approaches. Dr. Hubert Chen, accomplished drug developer…
Allakos, a clinical stage biotechnology company focused on developing novel therapeutics for allergy, inflammatory and proliferative diseases, named Dr. Lee as Chief Medical Officer. Dr. Lee has over 20 years of clinical research and development experience in the biopharmaceutical industry and academia across multiple therapeutic areas, including rheumatology, dermatology, allergy & asthma, and gastroenterology, focused…
Metagenomi, a precision genetic medicines company committed to developing curative therapeutics for patients by leveraging its metagenomics-derived genome editing toolbox, named Pamela Wapnick, MBA, as Chief Financial Officer. Pamela Wapnick has more than 20 years of diversified financial leadership experience spanning strategic and operational finance roles. Prior to joining Metagenomi, Pamela served as Chief Financial Officer at several biotech…
Ambrx Biopharma, a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system, named Renu Vaish, M.Sc., as Chief Regulatory Officer. Ms. Vaish is an experienced leader in U.S. and global regulatory affairs with extensive…
Chartwell Partners proudly announces its collaboration with Neurogene Inc., a pioneering clinical-stage company dedicated to delivering groundbreaking genetic therapies for individuals and families grappling with rare neurological conditions on the recruitment of Julie Jordan, M.D., as their esteemed Chief Medical Officer. With a wealth of experience spanning over two decades in both industry and clinical…